Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Strs Ohio

Strs Ohio decreased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 12.5% during the fourth quarter, HoldingsChannel reports. The firm owned 5,600 shares of the company’s stock after selling 800 shares during the quarter. Strs Ohio’s holdings in Krystal Biotech were worth $694,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its stake in Krystal Biotech by 111.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after purchasing an additional 379 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Krystal Biotech in the third quarter worth $219,000. Prime Capital Investment Advisors LLC acquired a new stake in shares of Krystal Biotech in the fourth quarter worth $310,000. Graham Capital Management L.P. acquired a new stake in shares of Krystal Biotech in the third quarter worth $330,000. Finally, Confluence Wealth Services Inc. increased its stake in shares of Krystal Biotech by 20.7% in the third quarter. Confluence Wealth Services Inc. now owns 2,920 shares of the company’s stock worth $339,000 after acquiring an additional 500 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS stock opened at $155.68 on Friday. The firm has a market cap of $4.44 billion, a PE ratio of 1,946.24 and a beta of 0.85. The firm’s fifty day moving average is $163.46 and its 200 day moving average is $131.32. Krystal Biotech, Inc. has a one year low of $82.09 and a one year high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 26th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of ($0.52) by $0.82. The firm had revenue of $42.14 million for the quarter, compared to analyst estimates of $27.43 million. During the same quarter in the prior year, the business posted ($1.25) EPS. Research analysts predict that Krystal Biotech, Inc. will post 1.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on KRYS shares. Citigroup increased their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a research note on Monday. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Stifel Nicolaus reiterated a “buy” rating and issued a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Finally, Guggenheim increased their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $171.00.

Insider Activity

In other news, CAO Kathryn Romano sold 8,087 shares of Krystal Biotech stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the sale, the chief accounting officer now owns 12,556 shares in the company, valued at $1,719,041.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CAO Kathryn Romano sold 8,087 shares of Krystal Biotech stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the sale, the chief accounting officer now owns 12,556 shares in the company, valued at $1,719,041.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold a total of 38,087 shares of company stock worth $6,210,591 over the last 90 days. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).